H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

Zymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.

Zymeworks (ZYME) received FDA approval for Ziihera in treating HER2+ gastroesophageal adenocarcinoma. The drug, licensed to Jazz Pharmaceuticals (JAZZ), qualifies for a $250 million milestone payment, with potential future payments up to $1.3 billion. ZYME shares fell 9.92%, while JAZZ shares rose 3.96%.

Zymeworks Inc. (ZYME) announced FDA approval for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line HER2+ GEA treatment. This marks the second FDA approval for zanidatamab in under two years, triggering a $250 million milestone payment from Jazz Pharmaceuticals. Zymeworks could receive up to $1.3 billion in additional milestones and royalties from Jazz, and up to $144 million from BeOne Medicines. The approval is based on Phase 3 trial resul

Zymeworks (ZYME) stock rose 4% in pre-market trading ahead of an FDA decision on its HER2-targeting antibody, zanidatamab, which could trigger a $250M milestone payment. Analysts raised price targets, and the company's acquisition of Theravance Biopharma for $929M adds to investor optimism, despite a weak broader market.